News
Apr 30, 2026
The U.S. Food and Drug Administration (FDA) has granted fast track designation to coramitug, an experimental treatment in late-stage clinical testing for…
Apr 28, 2026
Key TakeawaysATTR-CM results from TTR accumulation causing ventricular thickening and diastolic dysfunction, presenting with dyspnea, edema, congestion, tachycardia…
Apr 28, 2026
ATTR-CM is the zebra hiding among the horses. AI may finally be the tool that finds it. Experts Drs Kevin Alexander and Lily Stern explore what's working, what's…
Apr 28, 2026
The FDA granted Fast Track Designation to coramitug, an investigational anti-TTR antibody designed to clear existing amyloid deposits in ATTR cardiomyopathy.The US…
Apr 28, 2026
AboutThe purpose of this study is to investigate the effect of eplontersen compared to placebo on the reduction of serum TTR concentration and long-term safety in…
Apr 28, 2026
Transthyretin (ATTR) amyloidosis is a progressive fatal disease caused by the deposition of transthyretin derived amyloid fibrils in various organs [1]. The disease…
Apr 27, 2026
DUBLIN - The U.S. Food and Drug Administration has granted Fast Track Designation to coramitug, an investigational antibody for treating ATTR amyloidosis with…
Apr 27, 2026
Patients enrolled in more recent clinical trials for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) exhibited baseline characteristics consistent with less…
Apr 27, 2026
Coramitug is a potential best-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy1-3Coramitug is being evaluated by Novo…
Apr 25, 2026
AbstractBackgroundLarge-scale, nationwide data for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in Japan are limited.ObjectivesThis multicenter…